Document is current
Any future updates will be listed below
-
Authors
Khurana, Arushi
Rosenthal, Allison C.
Mohty, Razan https://orcid.org/0000-0002-0189-8233
Gaddam, Mamatha
Bansal, Radhika https://orcid.org/0000-0003-0964-098X
Hathcock, Matthew A.
Nedved, Adrienne N.
Durani, Urshila https://orcid.org/0000-0003-1860-2424
Iqbal, Madiha https://orcid.org/0000-0001-6752-5440
Wang, Yucai https://orcid.org/0000-0002-1576-8341
Paludo, Jonas https://orcid.org/0000-0002-7350-5531
Villasboas, J. C. https://orcid.org/0000-0002-2907-0809
Dingli, David https://orcid.org/0000-0001-7477-3004
Kourelis, Taxiarchis https://orcid.org/0000-0001-8573-9434
Leung, Nelson https://orcid.org/0000-0002-5651-1411
Alkhateeb, Hassan
Ruff, Michael W.
Gallo de Moraes, Alice
Vergidis, Paschalis
Herrmann, Joerg https://orcid.org/0000-0001-6675-4559
Kenderian, Saad S. https://orcid.org/0000-0003-2767-3830
Bennani, N. Nora https://orcid.org/0000-0001-8358-5953
Johnston, Patrick B.
Ansell, Stephen M. https://orcid.org/0000-0003-1244-6758
- License Information
-
More Information
Article History
Received: 7 April 2023
Revised: 27 July 2024
Accepted: 31 July 2024
First Online: 12 August 2024
Competing interests
: J.P. received research funding from Karyopharm. Y.W. received funding from Incyte, LOXO Oncology, Novartis, Genetech, and Morphosys; also had Incyte, LOXO Oncology, Eli Lilly, TG Therapeutics membership on advisory committee. Y.L. received research funding from Kite, Janssen, Celgene, Bluebird Bio, Merck, and Takeda; also received consulting fees from Janssen, Novartis, Celgene, Bluebird Bio, Juno, Legend, Sorrento, Gamida Cell, and Vineti. Also, LOXO Oncolgy, Incyte, Eli Lilly, and TG Therapeutics were taking part on an advisory committee. Stephen Ansell received from Bristol Myers Squibb, ADC Therapeutics, Seattle Genetics, Regeneron, Affimed, AITherapeutics, Pfizer, Trillium and Takeda.
